Wockhardt Generics Company Intelligence Report

Summary

Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Contents

• Executive Summary
• Introduction
  • Products
  • Wockhardt ANDA Approvals, 2002-2009
  • Morton Grove ANDA Approvals, 2002-08
  • Recent product approvals
  • Ranitidine (US)
  • Sumatriptan (US)
  • Levetiracetam (US)
  • Divalproex (US)
  • Wockhardt launches new insulin product in India
  • Wockhardt launches midazolam in the US
  • Wockhardt gains ceftazidime approval
  • Azithromycin
  • Sertraline
  • Financial results
  • Latest Quarterly Results, Q408
  • Wockhardt: Consolidated Fourth Quarter Results, in Rs millions
  • Wockhardt: Consolidated Fourth Quarter Results, in US$ millions
  • Latest Fiscal Year, FY2007
  • Wockhardt: Consolidated Full Year Results, Fiscal year to 31st December in Rs millions
  • Wockhardt: Consolidated Full Year Results, Fiscal year to 31st December in US$ millions
  • Sales by Region
  • Wockhardt: Consolidated Full Year Results by Region, Fiscal year to 31st December in Rs millions
  • Wockhardt: Consolidated Full Year Results by Region, Fiscal year to 31st December in US$ millions
• Major developments
  • Wockhardt to restructure its R&D business
  • Mergers, acquisitions and agreements
  • Wockhardt signs in-licensing agreement with DSM Nutritional
  • Sinclair Pharma
  • IDC and Wockhardt co-develop insulin pens for Indian market
  • Litigation
  • Orion and Wockhardt settle entacapone-based products litigation
  • Forest and Merz file lawsuits for memantine patent infringement
  • Contact Details